Figure 1: Complete A20 tumor regression following intratumoral injections of rR9-GRIM19 were elicited mainly by CD8+ T cells. A20 were subcutaneously inoculated into naïve mice on day 0, rR9-GRIM19 or rR9-GFP (control) fusion proteins were injected intratumorally (or peritumorally) daily for three days (days 9, 10, and 11) into A20 tumor-bearing normal BALB/c (A, D) or nude (B, C) mice. For adoptive transfer of T cells, purified CD3+, CD8+, or CD4+ (3×106) T cells from naïve BALB/c mice were intravenously infused into A20 tumor-bearing nude mice on day 0 (C). Antitumor effects of treatments were also investigated by intraperitoneal injections of anti-CD4 or anti-CD8 mAbs (on days 7 and 11) or anti- Ly-6G mAb (on days 7, 9, and 11) or control rat IgG (D). Data are representative of three individual experiments (** p < 0.01). Data from only one representative experiment (average tumor index from each treatment group) is shown.